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Introduction
Gastrointestinal stromal tumors (GISTs) are a 
heterogeneous group of tumors which comprise the 
most common primary mesenchymal tumors of the 
gastrointestinal tract (GIT) and occur throughout the 
GIT from esophagus to rectum (Rubin, 2006; Leigl-
Atzwangar, et al., 2012). The commonest site for GISTs is 
stomach (approximately 60%) followed by small intestine 
(excluding duodenum) (Nilsson et al., 2005; Miettinen et 
al., 2010). About 85-90% GISTs harbor a mutation of KIT 
(CD117), a tyrosine kinase receptor which is normally 
expressed by the ‘pacemarker’ interstitial cells of cajal 
located in the wall of the gut. These cells coordinate the 
autonomic nervous system of the gut and the smooth 
muscle cells to regulate motility and peristalsis. Most 
GISTs therefore originate in the submucosa or muscularis 
propria. The remaining 5 to 15% GISTs contain PDGFRA 
activity mutations (Heinrich et al, 2002; Hornick and 
Fletcher, 2004). The KIT mutation results in the activation 
of the Tyrosine kinase receptor allowing the detection of 
KIT (CD117) mutation by immunohistochemistry and 
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Abstract
 Purpose: To describe the clinicopathological features of gastrointestinal stromal tumors (GIST) diagnosed in 
our section and to perform risk stratification of our cases by assigning them to specific risk categories and groups 
for disease progression based on proposals by Fletcher et al and Miettinen and Lasota. Materials and Results: 
We retrieved 255 cases of GIST diagnosed between 2003 and 2014. Over 59% were male. The age range was 
16 to 83 years with a mean of 51 years. Over 70% occurred between 40 and 70 years of age. Average diameter 
of tumors was 10 cms. The stomach was the most common site accounting for about 40%. EGISTs constituted 
about 16%. On histologic examination, spindle cell morphology was seen in almost of 85% cases. CD117 was the 
most useful immunohistochemical antibody, positive in 98%. Risk stratification was possible for 220 cases. Based 
on Fletcher’s consensus proposal, 62.3 gastric, 81.8% duodenal, 68% small intestinal, 72% colorectal and 89% 
EGISTs were assigned to the high risk category; while based on Miettinen and Lasota’s algorithm, about 48% 
gastric, 100% duodenal, 76% small intestinal, 100% colorectal and 100% EGISTs in our study were associated 
with high risk for disease progression, tumor metastasis and tumor related death. Follow up was available in 
95 patients; 26 were dead and 69 alive at follow up. Most of the patients who died had high risk disease and 
on average death occurred just a few months to a maximum of one to two years after initial surgical resection. 
Conclusions: Epidemiological and morphologic findings in our study were similar to international published 
data. The majority of cases in our study belonged to the high risk category.  
Keywords: Gastrointestinal stromal tumor - extra gastrointestinal tumor - risk stratification - Pakistan
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helps in confirming the histologic diagnosis of GIST 
(Heinrich et al., 2002; Coindre et al., 2005; Zhang et al., 
2009; Miettinen et al., 2010). Most patients are elderly, 
median age ranges between 58 and 66 years (Coindre et al., 
2005; Tryggvason et al., 2005; Cao et al., 2010; Miettinen 
et al., 2010). However, no definite gender predilection 
has been reported. Histologically, most tumors in all 
sites show a spindle cell appearance (75 to 80%), while 
epithelioid cell or mixed morphology is seen in minority 
of cases (Coinder et al., 2005; Miettenin and Lasota, 2006; 
Miettenin et al., 2010). Small intestinal GISTs are twice as 
likely to behave as clinically malignant tumors compared 
to gastric GISTs, while most colorectal GISTs are very 
aggressive and advanced tumors with a poor prognosis 
(Mittenin et al., 2010a; 2010b).
GISTs can also occur outside the GIT mainly in the 
omentum, mesentery and retroperitoneum where they 
need to be distinguished from other mesenchymal tumors, 
especially from benign and malignant smooth muscle 
tumors (Reith et al., 2000). 
The most important prognostic factors on the basis 
of which GISTs are categorized into distinct prognostic 
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groups are tumor size and number of mitoses per 50 
high power fields (HPFS) (Miettenin et al., 2010). The 
consensus proposal by Fletcher et al. (2002) combined 
these two (size and mitotic activity) to divide GISTs into 
risk categories, while Miettenin and Lasota also added the 
anatomic location to provide comprehensive information 
about the prognosis (Miettenin and Lasota, 2006).
The aim of our study was to present the epidemiologic 
data of our cases, describe the morphologic (including 
Immunohistochemical) features, and perform risk 
stratification by assigning our cases into specific risk 
categories and groups based on both the consensus 
proposal (Fletcher et al., 2002) and the more elaborate risk 
prediction algorithm (Miettinen and Lasota, 2006). Follow 
up, where available, was taken and recorded. 
Materials and Methods
A total of 255 cases (stomach, duodenum, small 
intestine, colorectal and extra gastrointestinal) diagnosed 
in the Section of Histopathology, Aga Khan University 
Hospital, Karachi between the years 2003 and 2014 were 
included in the study. Clinical data such as age, gender, 
tumor location, tumor size, signs and symptoms and follow 
up were recorded. Histological features including spindle 
cell or epithelioid or mixed pattern and mitotic activity per 
50 HPFs were noted. Immunohistochemical reactivity to 
the following antibodies was noted: CD117, CD34, DOG 
1, Anti- Smooth muscle Actin (ASMA) and S100 protein.
Risk stratification was performed using tumor location, 
tumor size and mitotic activity / 50 HPFs, and the cases 
were assigned to specific risk categories and groups.
Statistical analysis was performed using SPSS 19.0 
version.
Results 
A total of 255 cases were included. Age of the patients 
ranged from 16 to 83 years with mean and median age of 
51 and 52 years respectively. The decade wise distribution 
is shown in Table 1. As shown in this table, over 70% 
were between 40 and 70 years of age. Out of 255, 151 
(59.2%) patients were males, and 104 (40.8%) were 
females. Male: female ratio was 1.4:1. Of the 255 cases, 
35 (13.7%) were small core biopsies while 220 (86.3%) 
were resection specimens. The size of the tumors ranged 
from 2.0 cms to 26 cms with an average size of 10 cms 
in the largest dimension.
Stomach was the commonest site in our series 
followed by the small intestine. The site wise breakup is 
shown in Table 2. Almost 46% of all cases were located 
in the stomach while over 27% were located in the small 
intestine. Extra GI GISTs comprised 41 cases (16.10%).
Grossly, majority of tumors were submucosal or 
intramural, nodular bulging masses, many with central 
ulceration. Some were polypoid and protruded into the 
gastric lumen (Figure 1A,B). Majority of our small 
intestinal and colorectal GISTs were polypoid with 
protrusion into the lumen and were less commonly 
intramural.
Out of 255 cases, 216 (84.7%) showed spindle cell 
morphology, 32 (12.5%) showed epithelioid morphology, 
while 7 cases (2.7%) were mixed (Figure 2A,B).
Immunohistochemistry was performed on most 
cases (Figure 3A,B). The antibodies employed and 
immunohistochemistry results are summarized in Table 
3. The antibody DOG1 was acquired in 2013. Hence, this 
antibody was used only in the recently diagnosed cases.
Risk stratification and assigning of cases into specific 
risk categories and groups was done based on the studies 
(Fletcher et al., 2002; Miettinen and Lasota, 2006). Risk 
stratification was not possible on 35 cases as these were 
small core biopsies. It was thus performed on 220 cases. 
These included 98 out of 117 cases of gastric GIST, 50 
out of 56 cases of jejunal and ileal GISTs, 11 out of 14 
cases of duodenal GISTs, 25 out of 27 cases of colorectal 
GISTs, and 36 out of 41 cases of extra GI GISTs. The 
findings are shown in Tables 4 and 5.
Follow up was available in 95 out of 220 cases. Of 
these 95 patients, 69 are alive, while 26 patients died. 
Table 1. Decade Wise Age Distribution of our Cases 
(n=255)
S No. Decade Number Percentage%
1 11-20 2 0.80%
2 21-30 13 5.10%
3 31-40 33 12.90%
4 41-50 58 22.70%
5 51-60 59 23.10%
6 61-70 62 24.30%
7 71-80 25 9.80%
8 >80 3 1.20%
Table 2. Site Wise Distribution of our Cases (n=255)
S No. Site Number Percentage%
1 Esophagus 1 0.40%
2 Stomach 117 45.90%
3 Duodenum 14 5.50%
4 Jejunum 22 8.60%
5 Ileum 34 13.30%
6 Colorectum 26 10.20%
7 Mesentery 23 9.10%
8 Retroperitoneum 10 3.90%
9 Omentum 8 3.10%
Table 3. Immunohsitochemical Profiles of Cases in our Study (n=255)
S No. Immunohistochemical antibody Positive Focal positive Negative Not performed
1 CD 117 242 (94.9%) 8   (3.1%) 5   (2%) ---
2 CD 34 169 (70.4%) 14   (5.8%) 57 (23.8%) 15
3 DOG 1 18 (72.0%) 2   (8%) 5 (20%) 230*
4 Smooth Muscle Actin (ASMA) 67 (29.4%) 45 (19.7%) 116 (50.9%) 27
5 S 100 protein 64 (30.3%) 29 (13.7%) 118 (56%) 44
*acquired in 2013
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Of the latter, 1 patient had a very low risk gastric GIST. 
However, he had a concomitant gastric adenocarcinoma 
with positive lymph nodes, and died as a result of 
complications secondary to the adenocarcinoma. Of 
the remaining 25 patients, 22 had high risk while 2 had 
moderate risk disease. The disease was located in the 
stomach in 10 cases, small intestine (ileum and jejunum) 
in 4 cases, duodenum in 2 cases and colorectum in 4 
Table 4.  Risk Stratification. Assignment of Cases in our Series into Risk Categories Based on Fletcher et al’s 
Proposal(18) (n=220)
S. No.      Site Number Very Low Risk * Low Risk ** Intermediate Risk *** High Risk ****
1 Stomach 98 3 (3.1%) 17 (17.3%) 17 (17.3%) 61 (62.3%)
2 Duodenum 11 --- --- 2 (18.2%) 9 (81.8%)
3 Jejunum + Ileum 50 --- 5 (10%) 11 (22%) 34 (68%)
4 Colorectum 25 --- 2 (8%) 5 (20%) 18 (72%)
5 Mesentery  19 --- --- 1 (5.3%) 18 (94.7%)
6 Retroperitoneum 13 --- --- 3 (23.1%) 10 (76.9%)
7 Omentum 4 --- --- --- 4 (100%)
*> 2 cms, > 5 M / 50 HPF; **2-5 cms, > 5 M / 50 HPF; ***<5 cms, 6-10 M / 50 HPF;  or 5-10 cms, < 5 M / 50 HPF; ****>5 cms, > 5 M /50 HPF; 
or > 10 cms, any no. of mitoses; or any size, > 10 M /50 HPF
Table 5. Risk Stratification. Assignment of Cases in our Series into Risk Groups Based on Miettinen and Lasota’s 
Algorithm(14) (n=220)
S. No. Site  Number Group 1 Group 2 Group 3a Group 3b Group 4 Group 5 Group 6a Group 6b
1 Stomach  98 5 (5.1%) 15 (15.3%) 10 (10.2%) 8   (8.2%) --- 13 (13.3%) 20 (20.4%) 27 (27.5%)
2 Duodenum 11   1   (9.1%)   1   (9.1%) 1   (9.1%) 8 (72.7%)
3 Jejunum+Ileum  50 --- 5 (10%) 7 (14%) 13 (26%) --- 4   (8%) 7 (14%) 14 (28%)
4 Colorectum  25 --- --- 2   (8%) 3 (12%) --- 7 (28%) 6 (24%) 7 (28%)
5 EGISTs  36 --- --- 2   (5.5%) 6 (16.7%) --- 2   (5.5%) 3   (8.3%) 23 (63.9%)
*Group 1:> 2 cms, < 5 M / 50 HPF; Group 2: 2-5 cms, < 5 M / 50HPF; Group 3a:5-10 cms, < 5 M / 50HPF; Group 3b:>10 cms, < 5 M / 50HPF; 
Group 4:<2 cms, > 5 M / 50HPF; Group 5:2-5 cms, > 5 M / 50HPF; Group 6a:5-10 cms, > 5 M / 50HPF; Group 6b:> 10 cms, > 5 M / 50HPF 
Table 6. Data of Patients who were Dead at Follow Up (n=26)
S. No. Site Risk Category Group Gleevec Status Year of Surgery Year of Death
1 Retroperitoneum High 6b No 2004 2006 
2 Jejunum High 6b Yes 2004 2007
3 Stomach (a) High 6b Yes 2004 2006
4 Stomach High 6a Yes 2005 2005
5 Stomach High 6b Yes 2005 2007
6 Colorectum High 6a Yes 2006 2006
7 Jejunum (b) Moderate 3a Yes 2006 2012
8 Duodenum High 6a No 2006 2006
9 Retroperitoneum (c) High 6b No 2008 2008
10 Colorectum (d) High 6b Yes 2009 2011
11 Stomach (e) High 6b Yes 2009 2009
12 Colorectum (f) High 6b Yes 2009 2011
13 Jejunum (g) High 6b No 2009 2009
14 Retroperitoneum (h) High 6b Yes 2009 2010
15 Stomach (i) Moderate 5 No 2010 2011
16 Stomach High 6b No 2010 2010
17 Mesentery High 6b No 2011 2012
18 Mesentery High 6a No 2011 2011
19 Colorectum High 6b No 2011 2013
20 Ileum High 6a Yes 2011 2012
21 Stomach (j) High 6b No 2012 2012
22 Stomach (k) Very Low 2 No 2012 2012
23 Duodenum (l) High 6a Yes 2012 2012
24 Stomach (m) Moderate 5 Yes 2013 2014
25 Retroperitoneum (n) High 6b Yes 2013 2013
26 Stomach High 6a Yes 2013 2014
* Note: Additional information available: (a) Metastasis to kidney and heart, died in 2006; (b) Took Gleevec continuously, no history of recurrence 
or metastases; (c) Died immediately after surgery; (d) Took Gleevec regularly, died during surgery for excision of recurrent tumor; (e) Took Gleevec 
regularly until death seven months after surgery; (f) Took Gleevec regularly until death two years after surgery; (g) Died immediately after surgery; 
(h) Took Gleevec regularly until death six months after surgery; (i) Died of liver failure in 2011 (had chronic Hepatitis C); (j) Died soon after surgery; 
(k) Very low risk disease, died three months after surgery from widespread metastases of concomitant colorectal adenocarcinoma; (l) Died four 
months after surgery, took Gleevec regularly; (m) Took Gleevec regularly, died about one year after surgery, possibly due to some unrelated cause; 
Took Gleevec regularly until death four months after surgery
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cases, while 6 cases represented EGISTs. Out of the 26 
patients, 15 had been treated with Gleevec, while 11 did 
not receive this treatment. The details of these 26 patients 
are given in Table 6.
Out of the 69 patients who are still alive, 47 had high 
risk disease, 15 had intermediate risk, 5 had low risk and 2 
patients had very low risk disease. Of these 69 patients, 4 
patients had one or more recurrences and 6 had metastatic 
disease at the time of follow up. The disease was located 
in the stomach in 32 out of 69 cases, in the small intestine 
(ileum and jejunum) in 19 cases, duodenum in 1 case, 
colorectum (including anal region) in 10 cases, and 
esophagus in 1 case, while EGISTs accounted for 6 cases. 
Out of the 69 patients, 52 had been treated with Gleevec, 
while 17 patients did not receive this treatment. The details 
of these 69 patients are given in Table 7. 
Discussion
In 2013, we published an epidemiological and 
histological perspective of diseases of the gastrointestinal 
tract in Pakistan (Ahmad et al., 2013). In the current article, 
an epidemiological, histological and risk stratification 
perspective of GIST is presented.
As shown in the results, mean age was 51 years and 
the highest number of cases were diagnosed in the fifth, 
sixth and seventh decades (Table 1). The mean age is much 
lower in our series than reported in Western and even Asian 
literature where mean ages of gastric and small intestinal 
GISTs have varied from 58 to 70 years (Coindre et al., 
2005; Tryggvason et al., 2005; Cao et al., 2010; Miettinen 
et al., 2010; Wang et al., 2013). GISTs in all locations 
occur in the elderly, less than 10% gastric GISTs occur 
in patients below 40 years of age (Miettinen and Lasota, 
2006). In our study, almost 19% GISTs occurred below 
the age of 40 years (Table 1). Studies have shown no 
gender predilection, although some studies demonstrate 
a mild male predominance i.e. 52 to 55% in GISTs in all 
locations (Cao et al., 2010; Miettenin et al., 2010). In our 
study, over 59% patients were males. The average size of 
tumors in our study was 10 cms and size ranged from 2 to 
26 cms. Various studies have reported sizes ranging from a 
few millimeters to greater than 20 cms for small intestinal, 
and a few millimeters to greater than 40 cms for gastric 
GISTs (Miettinen and Lasota, 2006). In the largest series 
of gastric GISTs published (Miettinen et al., 2005), the 
mean size for gastric GISTs was 6 cms. In two separate 
studies, from Iceland and China, mean tumor size was 4.6 
cms and 7.02 cms respectively (Tryggvason et al., 2005; 
Cao et al., 2010). Symptoms in our cases were variable; 
the commonest were vague abdominal pain, abdominal 
mass, heart burn, bleeding per rectum, hematemesis, 
anemia etc. Grossly, majority of our gastric tumors were 
submucosal or intramural, nodular bulging masses, many 
with central ulceration. Some were polypoid and protruded 
into the gastric lumen. Majority of our small intestinal 
and colorectal GISTs were polypoid with protrusion into 
the lumen and were less commonly intramural. Similar, 
gross appearances have been described by various authors 
(Rosai, 2003; Miettenin and Lasota, 2006).
In our series, stomach was the commonest site, (almost 
46%), while almost 22% were located in the small intestine 
(jejunum and ileum excluding duodenum). If duodenum 
Table 7. Data of Patients who were Alive at Follow Up-Site wise Breakup (n=69)
 Year Resected Treated with Risk Category
  Gleevec 
Site No. of 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Yes No V. low low Inter- High Recur- Meta-
 Cases              risk risk mediate risk rence stases
                 risk
Esophagus 1 - - - - - - - 1 - - - 1 - - 1 - - - -
Stomach 32 1 - - - - 1 4 9 5 12 - 23 9 2 4 9 17 1 4
Duodenum 1 - - - - - 1 - - - - - 1 - - - - 1 - -
Small Intestine 19 - 2 1 - 1 3 6 2 2 2 - 13 6 - 1 5 13 1 1
(Jejunum+Ileum)
Colorectum 10 - - - - - 1 3 2 3 1 - 8 2 - - 5 5 2 1
EGISTs 6 - - - - - 1 1 3 - 1 - 6 - - - 3 3 - -
Figure 1. A) Gross Appearance of GIST of Stomach 
Protruding into the Lumen; B) GIST of Stomach with 
a Fleshy Cut Surface
Figure 2. A) Spindle cell GIST Arranged in Fascicles. 
B) Sheets of Epithelioid Cells with Eosinophilic 
Cytoplasm in Epithelioid GIST
Figure 3. CD117 (A) and DOG 1 (B) Positivity in GIST
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is included, over 27% cases were located in the small 
intestine (Table 2). According to various international 
studies, 59 to 61% GISTs occur in stomach (Nilsson et 
al., 2005; Tryggvason et al., 2005; Miettenin et al., 2006), 
about 30%  in the jejunum and ileum, and 4 to 5% occur 
in the duodenum (Miettenin et al.,2003). Colorectal GISTs 
comprise 4 to 5% (Miettenin et al., 2006, Cao et al., 2010). 
Compared to the international data, location in stomach 
and small intestine was slightly less common in our series 
while location in colon and rectum was slightly higher. 
However, a recent study from Turkey reported tumor 
location in the stomach in 45.6% cases, very similar to 
our findings (Selcukbiricik et al., 2013).
On histological examination, almost 85% cases 
showed spindle cell morphology while cases with 
epithelioid morphology comprised over 12%. Various 
international studies have reported the epithelioid type to 
comprise between 20-25%, with mixed tumors comprising 
the remaining 5 to 10% cases (Coinder et al., 2005; 
Miettenin et al., 2006; Miettenin et al., 2010).
Immunohistochemically, CD117 was the most useful 
antibody, being strong diffuse positive in almost 95%. 
CD 34 showed diffuse strong positivity in over 70%. We 
have limited experience with DOG1 since we acquired this 
antibody only in 2013.  It demonstrated diffuse positivity 
in 72%. We intend to use DOG1 in all future cases as this 
antibody has proved to be a very sensitive and specific 
marker for GISTs (Miettenin et al., 2009). Anti-Smooth 
Muscle Actin (ASMA) was diffuse or at least focal positive 
in about 49% cases, while S100 protein was diffuse or 
focal positive in 44% cases (Table 3).
Published Western literature shows that CD117 
positivity is seen in 95% (gastric) to 98% (small intestinal) 
GISTs, and CD34 positivity in 60-70% GISTs. However, 
CD34 positivity varies with positivity seen in 80 to 85% 
gastric, 50% small intestinal and 95 to 100% esophageal 
and colorectal GISTs. It has been seen that most spindle 
cell GISTs shown positivity for CD34 (Coinder et al., 
2005; Miettenin et al., 2005; Miettenin and Lasota, 2006; 
Miettenin et al., 2006). A study from China showed CD117 
positivity in 94.5% and CD34 positivity in 86.2% cases 
(Cao et al., 2010). Another Asian study showed CD117 and 
DOG 1 positivity in 90.5% and 84.1% cases respectively 
(Sun et al., 2012).
With regard to ASMA and S100 protein, positivity for 
the former has been reported in 20% of gastric and 35% of 
small intestinal GISTs, while positivity for the latter has 
been reported rarely (<1%) in gastric GISTs. However, 
positivity for S100 protein has been very variable with 
various studies reporting positivity in 14% to 50% cases. 
Studies have demonstrated that CD34 expression is not a 
significant prognostic factor for gastric and small intestinal 
GISTs. However, ASMA expression is a statistically 
significant favorable prognostic factor in gastric and 
small intestinal GISTs (Tworek et al., 1997; Miettenin 
et al., 2005; Miettenin et al., 2006). The prognostic and 
predictive potential of immunohistochemical stains in 
GIST has been studied but results are conflicting and 
inconclusive (Sun et al., 2012; Demir et al., 2013).
Over 16% cases in our series were diagnosed as 
extra gastrointestinal GISTs (EGISTs) and most of these 
were high risk (Tables 4&5). While EGISTs definitely 
represent bona fide and true GISTs, and demonstrate 
CD117 immunohistochemical expression as well as GIST-
specific KIT mutations (Rosai et al., 2004; Yamamoto 
et al.,2004; Miettenin et al., 2013), their incidence in 
most series is extremely low, around 1% (Miettenin and 
Lasota, 2006). One study did not find a single convincing 
case among 200 cases (Agaimy and Wunsch, 2006). 
However, EGISTs comprised 10% of all GISTs in a 
study from Korea (Cho et al., 2010). The current concept 
is that most so called EGISTs are actually detachments 
or metastases from GISTs of primary gastrointestinal 
tract origin (Miettenin and Lasota, 2006; Miettenin et 
al., 2013). We get a lot of referral cases from all over 
Pakistan, a large country with a population of 190 million, 
and accurate surgical details or radiological films are not 
available in many cases. It is quite possible that many 
of the so called EGISTs in our series actually represent 
involvement of retroperitoneum, omentum, mesentery 
etc by gastrointestinal stromal tumors. Studies have 
looked for parameters that can clearly identify bona fide 
EGISTs. Matrix metalloproteinases (MMPs), which are 
molecules that are implicated in metastasis by various 
malignant tumors, have been investigated for their role 
in contributing to the ability of EGISTs to metastasize. 
A recent study demonstrated that increased MMP-2 and 
MMP-9 expression was associated with increased risk of 
metastasis and aggressive behavior in E-GISTs (Wang et 
al., 2014).
The evaluation of prognosis is essential in GIST. 
Every GIST carries a risk and potential for malignant 
behavior and there is increasing reluctance to label any 
GIST as benign. However, this risk varies from very low 
to very high (Coinder et al., 2005; Miettenin et al., 2013). 
Earlier studies showed that about 50% primary localized 
GISTs relapsed within the first five years (local recurrence 
within the peritoneal cavity or liver metastases) while a 
much greater percentage of GISTs relapsed within ten 
years, and that if relapse occurred, prognosis was almost 
invariably poor (Franquemont, 1995; Emory et al., 1999; 
DeMatteo et al., 2000). It became increasingly clear that 
it was not practically possible to divide GISTs into benign 
or malignant categories based on morphology alone 
and the emphasis shifted to determining criteria which 
could assess the risk of GISTs to behave in a malignant 
fashion. Several schemes were developed to define criteria 
which can stratify the risk of malignant behavior and by 
which GISTs can be assigned to definite risk categories 
(low, intermediate, high) or groups (Franquemont, 1995; 
Fletcher et al., 2002; Miettenin and Lasota, 2006). Tumor 
size and number of mitoses per 50/HPFs emerged as the 
major criteria. It also became clear that location was 
extremely important, with non-gastric GISTs harboring 
a much higher risk for malignant behavior compared to 
gastric GISTs of comparable size and mitotic activity 
(Tryggvason et al., 2005; Miettenin and Lasota, 2006). 
Other histologic factors including cellularity, coagulative 
necrosis, mucosal invasion etc have been suggested 
(Miettenin et al., 2005; Tryggvason et al., 2005; Miettenin 
et al., 2006). Currently, the risk stratification is based on 
the consensus proposal (Fletcher et al., 2002) and the risk 
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prediction algorithm (Miettinen and Lasota, 2006). Based 
on these, over 62% of gastric, almost 82% duodenal, 68% 
small intestinal (jejunum and ileum), 72% colorectal, 
95% mesenteric, 77% retroperitoneal and 100% omental 
GISTs in our series belonged to high risk category (Table 
4). In a recent study from Turkey which looked at 249 
cases, 47% cases belonged to the high risk category 
(Selcukbiricik et al., 2013). Other recent studies from Asia 
have also risk stratified GISTs based on the above criteria 
(Chen et al., 2013). High risk tumors made up 70% and 
60% respectively of all cases in two studies from India 
(Lakshmi et al., 2010; Ravikumar et al., 2011).
Table 4 also shows that 3% of all gastric GISTs fell 
into the very low risk category, while 17.3% each fell into 
low risk and intermediate risk categories. Among jejunal 
and ileal GISTs, 10% and 22% fell into low risk and 
intermediate risk categories respectively, while 8% and 
20% colorectal GISTs fell into the low and intermediate 
risk categories. Of the so called EGISTs in our series, just 
over 5% of mesenteric and 23% retroperitoneal GISTs fell 
into the intermediate risk category.
Based on Miettinen and Lasota’s study (Miettinen 
and Lasota ,2006), over 5% of gastric GISTs in our study 
fell into ’Group 1’ which is not associated with any risk 
for progressive disease, tumor metastases and /or tumor 
related death. These were the only tumors in our study 
which fell in group 1 (Table 1). Over 15% of  gastric and 
10% of jejunal and ileal GISTs in our study fell into ‘Group 
2’ which is associated with very low risk for progressive 
disease, metastases and tumor related death for gastric 
and low risk for  GISTs in all other locations. Just over 
10% gastric and 9% duodenal GISTs, 14% small intestinal 
(jejunal and ileal), 8% colorectal, and over 5% EGISTs fell 
in ‘Group 3a’ which is associated with low risk for gastric 
and moderate risk for ileal and jejunal GISTs. Slightly 
over 8% gastric, 26% small intestinal (jejunal and ileal), 
12% colorectal and almost 17% EGISTs fell in ‘Group 3b’ 
according to Miettinen’s algorithm. Group 3b is associated 
with moderate risk for gastric and high risk for jejunal 
and ileal GISTs. Miettinen and Lasota (Miettinen and 
Lasota, 2006) combined groups 3a and 3b in duodenal 
and colorectal GISTs due to small number of cases and 
the ‘Combined group 3’ is associated with high risk for 
duodenal and rectal GISTs. No tumor in our study fell 
into ‘Group 4’. Over 13% gastric, over 9% duodenal, 8% 
small intestinal, 28% rectal and over  5% EGISTs in our 
study fell in ‘Group 5’ which is associated with moderate 
risk for gastric and high risk for all other locations. Over 
20% gastric, over 9% duodenal, 14% jejunal and ileal, 
24% colorectal and over 8% EGISTs in our study fell into 
‘Group 6a’ which is associated with high risk for gastric as 
well as jejunal and ileal GISTs. Over 27% gastric, almost 
73% duodenal, 28% small intestinal (jejunal and ileal), 
28%  colorectal and almost 64% EGISTs in our study 
fell into ‘Group 6b’ which is associated with high risk for 
gastric as well as Jejunal and Ileal GISTs. Miettinen and 
Lasota (Miettinen and Lasota,2006) combined groups 6a 
and 6b in duodenal and  rectal GISTs due to small number 
of cases and the ‘Combined Group 6’ is associated with 
high risk for duodenal and colorectal GISTs. Jejunal and 
ileal, duodenal and rectal GISTs in groups 5, 6a and 6b, and 
gastric GISTs in groups 6a and 6b all carry a high risk for 
progressive disease, metastases and tumor related death. 
Gastric GISTs in groups 3b and 5 and jejunal and ileal 
GISTs in group 3a carry a moderate risk for progressive 
disease; gastric GISTs in group 3a, jejunal and ileal, 
duodenal and colorectal GISTs in group 2 carry a low 
risk for progressive disease; while gastric GISTs in group 
2 carry a very low risk for progressive disease, tumor 
metastasis and tumor related death (Miettinen and Lasota, 
2006). Earlier studies by Miettinen et al (Miettinen et al., 
2005; Miettinen et al., 2006) showed that about 16%, 55% 
and 86% of gastric GISTs in groups 5, 6a and 6b; 73%, 
85% and 90% of jejunal and ileal GISTs in groups 5, 6a 
and 6b; 50% duodenal and 52% rectal GISTs in group 5; 
while 86% duodenal and 71% rectal GISTs in combined 
group 6 developed progressive disease, tumor metastases 
and tumor related death.
Based on Fletcher et al.’s consensus approach (Fletcher 
et al.,2002), about 38% gastric GISTs in our study (Tables 
4 & 5) were assigned to the very low, low and intermediate 
risk categories while 62% are assigned to the high risk 
category. Using the more elaborate algorithm, developed 
by Miettinen and Lasota (Miettinen and Lasota,2006) , 
about 52% of gastric GISTs in our study were assigned 
groups 1, 2, 3a, 3b and 5 which are associated with no 
risk (group 1), very low risk (group 2), low risk (group 
3a) and moderate risk (group 3b and 5) and the remaining 
48% gastric GISTs were assigned groups 6a and 6b which 
are associated with high risk for disease progression, 
metastasis and tumor related death (Fletcher et al., 
2002). About 18% of duodenal GISTs in our series were 
assigned the intermediate risk category while 82% were 
assigned the high risk category. However, all our duodenal 
GISTs were assigned to groups 3, 5 and 6 all of which 
are associated with high risk in duodenal GISTs. About 
10% of small intestinal (jejunal and ileal) GISTs were 
assigned to the intermediate risk, and 68% were assigned 
to the high risk category. However, based on Miettinen 
and Lasota’s proposal (Miettinen and Lasota, 2006), 10% 
small intestinal GISTs in our study were assigned group 
2 (low risk), 14% were assigned group 3a (moderate 
risk) and the remaining 76% were assigned groups 3b, 
5, 6a and 6b all of which are associated with high risk 
for disease progression in jejunal and ileal GISTs. Based 
on Fletcher’s proposal [18], 8% and 72% of colorectal 
GISTs were assigned to the low risk and high risk category 
respectively. Based on Miettinen’s algorithm (Miettinen 
and Lasota,2006), all colorectal GISTs were assigned 
groups 3, 5 and 6 all of which are associated with high 
risk in colorectal GISTs.
About 11% EGISTs in our study were assigned to the 
intermediate risk and 89% to high risk category, but all 
were assigned groups 3, 5 and 6 which are associated with 
high risk of tumor progression in EGISTs.
The primary treatment of GISTs is surgical excision 
with adequate negative tumor margins. All patients in our 
series underwent resection, with negative surgical margins 
in all but 4 patients. 
Although surgical excision is the mainstay of therapy 
for GISTs, targeted therapy with Imatinib mesylate 
(Gleevec) which binds to KIT and inhibits intracellular 
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signaling, has shown spectacular results especially in 
patients with unresectable, recurrent and even metastatic 
tumors (Mechtersheimer et al.,2004). Although there 
is still no agreement on whether it should be given in 
the adjuvant or neoadjuvant setting, some authorities 
now recommend adjuvant treatment if the chances of 
recurrence are greater i.e. large tumor size, location 
other than gastric, high mitotic rate etc. Treatment is 
recommended for at least a year after surgery, while 
for tumors which are highly likely to recur, treatment is 
recommended for up to three years after surgery. A recent 
study showed that preoperative Imatinib was associated 
with improved surgical margins while perioperative 
Imatinib resulted in improved disease free and overall 
survival in rectal GISTs (Jakob et al., 2013). A study 
from India demonstrated the role of Imatinib in adjuvant 
and therapeutic settings and reported that responses 
were durable and most patients tolerated the drug well 
at clinically effective doses (Kapoor et al., 2013). Newer 
drugs, such as sunitinib are also coming up and may be 
effective in patients who become resistant to gleevec. A 
study by Li et al. on Chinese patients with gleevec resistant 
or intolerant GISTs showed that Sunitinib was effective 
in such patients and they tolerated this drug well (Li et 
al., 2012). Similar findings were reported by Yoon et al in 
Korean patients (Yoon et al., 2012). In turn, even newer 
drugs which may be useful in patients with advanced 
tumors and resistance to both imatinib and sunitinib are 
also coming up fast (DeMatteo et al., 2009; Blay et al., 
2010; Demetri et al., 2013; Joensuu et al., 2013). Recently, 
a study from China demonstrated that surgical removal 
of metastatic lesions of GISTs in patients who were 
also receiving and responding to Imatinib improved the 
outcome in such patients (Du et al., 2014). Thus the role 
of surgery in patients with recurrent or metastatic GISTs 
who were responding to Imatinib is currently a subject 
for additional research. 
A study by Sevinc et al. investigated cyclooxygenase 2 
(COX-2) expression in GIST. Their findings demonstrated 
that use of Cox-2 inhibitors, with or without Tyrosine 
Kinase inhibitors, may be helpful in the adjuvant setting 
in preventing or delaying recurrence (Sevinc et al., 2010). 
Follow up was available in 95 cases out of which 69 
patients are alive and 26 patients died. A glance at table 6 
shows that most of these patients, irrespective of location, 
had high risk tumors. Most of these patients lived on 
average a few months to one to two years after initial 
surgical resection. Only one patient, with an intermediate 
risk tumor in the jejunum, survived for 6 years after 
resection. It appears that at least for most of these 26 
patients who died, Gleevec status apparently did not 
significantly alter the clinical course. However, in a poor 
country like Pakistan, where compliance issues are very 
important, it is quite possible that poor response to Gleevec 
may in reality represent lack of compliance rather than 
failure of response to the drug. Of the 69 patients who are 
alive, the majority have high risk tumors irrespective of the 
location. Most of these patients had resections in the last 
four to five years (Table 7). As shown in Table 7, 3 patients 
with small intestinal GISTs, one with a low risk and two 
with intermediate risk tumors, have survived since their 
initial resection in 2005 and 2006. Conversely, 4 patients 
with high risk gastric GISTs who were initially operated 
in 2010 and later have developed early metastatic disease. 
As most of the 69 patients who are alive underwent initial 
resection relatively recently i.e. over the last four to five 
years (many as late as 2013), it may be too early yet 
to assess the impact of Gleevec therapy on the clinical 
course of these patients. A study from India showed that 
preoperative Gleevec resulted in enough downstaging in 
patients with locally advanced GIST allowing resection 
with negative margins in a fairly good proportion of such 
patients (Ashraf et al., 2011). Similarly, a recent study 
from Taiwan demonstrated that the outcome for patients 
with GIST has improved significantly with the availability 
and wider use of Gleevec (Chiang et al., 2014).
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